Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Drug Discovery Today|December 19, 2012
Torching the Haystack: modelling fast-fail strategies in drug developmentDennis W Lendrem, B Clare LendremDrug Discovery Today|September 21, 2013
The development speed paradox: can increasing development speed reduce R&D productivity?Dennis W Lendrem, B Clare LendremPharmaceutical Statistics|October 23, 2014
R&D productivity rides again?Dennis Lendrem, Stephen J Senn, B Clare Lendrem, et al.Diagnostic and Prognostic Research|August 18, 2023
Sample size determination for point-of-care COVID-19 diagnostic tests: a Bayesian approachS Faye Williamson, Cameron J Williams, B Clare Lendrem, et al.Journal of Internal Medicine|January 12, 2022
Primary Sjögren's syndrome: Longitudinal real-world, observational data on health-related quality of lifeJessica Tarn, Dennis Lendrem, Peter McMeekin, et al.NIHR Open Research|January 24, 2025
Mapping decision-making pathways: Determination of intervention entry points for diagnostic tests in suspected serious infectionRaasti Naseem, Nicola Howe, Sara Pretorius, et al.Nature Reviews. Drug Discovery|August 22, 2015
Why is it hard to terminate failing projects in pharmaceutical R&D?Richard W Peck, Dennis W Lendrem, Iain Grant, et al.International Journal of Molecular Sciences|March 14, 2026
Tissue-Based Transcriptomic Profiling of Gastrointestinal Graft Versus Host Disease Reveals Immune and MicroRNA DysregulationSakhila Ghimire, Jean Norden, Rihab Gam, et al.Drug Discovery Today|December 14, 2019
Schrödinger's pipeline and the outsourcing of pharmaceutical innovationPeter McMeekin, Dennis W Lendrem, B Clare Lendrem, et al.Oncoimmunology|April 14, 2017
IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development <i>in vivo</i>Margherita Boieri, Aina Ulvmoen, Amanda Sudworth, et al.Pageof 4